This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ocaña, A. Articles by Pandiella, A. Search for Related Content PubMed PubMed Citation Articles by Ocaña, A. Articles by Pandiella, A. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers Clinical Research: Response Markers and Mechanisms

Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options

Authors' Affiliations: ¹ Complejo Hospitalario Universitario de Albacete, Albacete, Spain and ² Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Cientificas-Universidad de Salamanca, Salamanca, Spain

Requests for reprints: Alberto Ocaña, Complejo Hospitalario Universitario de Albacete, C/Hermanos Falcó s/n, 02006 Albacete, Spain. E-mail: albertoo{at}sescam.jccm.es.

Although the introduction of novel therapies and drug combinations has improved the prognosis of metastatic breast cancer, this disease remains incurable. It is therefore important to develop additional novel therapeutic strategies and agents. Increased understanding of the biology and the molecular alterations present in breast cancer is facilitating the design of targeted therapies directed to oncogenic proteins. Here, we review the signaling pathways and proteins that participate in breast cancer proliferation and survival, with special emphasis in those that are druggable. We will also comment on how the knowledge on the basic pathogenetic processes is translated into drug development strategies that are reaching the breast cancer clinic.

This article has been cited by other articles:

				P.-L. Kuo, W.-C. Ni, E.-M. Tsai, and Y.-L. Hsu Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells Mol. Cancer Ther., May 1, 2009; 8(5): 1328 - 1339. [Abstract] [Full Text] [PDF]